Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)
Overview[ - collapse ][ - ]
Purpose | This is a 2-arm, randomized, double-blind, double-dummy, and controlled clinical study, with 6 months of treatment to evaluate the clinical and metabolic efficacy of DLBS3233 in improving reproductive parameters and to evaluate the safety of DLBS3233 in women with polycystic ovary syndrome compared with metformin, as an active control. |
---|---|
Condition | Polycystic Ovary Syndrome (PCOS) |
Intervention | Drug: DLBS3233 Drug: Metformin XR Drug: Placebo caplet of Metformin XR Drug: Placebo capsule of DLBS3233 |
Phase | Phase 3 |
Sponsor | Dexa Medica Group |
Responsible Party | Dexa Medica Group |
ClinicalTrials.gov Identifier | NCT01733459 |
First Received | November 21, 2012 |
Last Updated | March 7, 2014 |
Last verified | March 2014 |
Tracking Information[ + expand ][ + ]
First Received Date | November 21, 2012 |
---|---|
Last Updated Date | March 7, 2014 |
Start Date | March 2013 |
Estimated Primary Completion Date | February 2015 |
Current Primary Outcome Measures | HOMA-IR reduction [Time Frame: 6 months] [Designated as safety issue: No]HOMA-IR reduction from baseline to Month 6th (end of study) |
Current Secondary Outcome Measures |
|
Descriptive Information[ + expand ][ + ]
Brief Title | Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS) |
---|---|
Official Title | The Role of DLBS3233 in the Management of Polycystic Ovary Syndrome (PCOS) |
Brief Summary | This is a 2-arm, randomized, double-blind, double-dummy, and controlled clinical study, with 6 months of treatment to evaluate the clinical and metabolic efficacy of DLBS3233 in improving reproductive parameters and to evaluate the safety of DLBS3233 in women with polycystic ovary syndrome compared with metformin, as an active control. |
Detailed Description | There will be 2 groups of treatment; each group will consist of 62 subjects with the treatment regimens : - Treatment I : 1 capsule of DLBS3233 100 mg (once daily) and 1 placebo caplet of Metformin XR (twice daily) - Treatment II : 1 caplet of Metformin XR 750 mg (twice daily) and 1 placebo capsule of DLBS3233 (once daily) for 6 months of treatment. Clinical examination to evaluate the efficacy of the investigational drug will be performed at baseline and every interval of 1 month. Laboratory examinations to evaluate the metabolic efficacy parameters and ultrasonography (USG) examination will be performed at baseline, Month 3rd, and end of study (Month 6th). In addition to that, USG will also be performed about 2 weeks after Month 3rd (Month 3.5th) and after Month 5th (Month 5.5th). Laboratory examinations to evaluate the reproductive efficacy parameters (reproductive hormone levels) and safety, at baseline and Month 6th (end of study). General counseling on lifestyle modification will be provided to the subjects by the assigned Nutritionist. All study subjects should follow a lifestyle modification. Evaluation on subjects' performance on lifestyle modification will be conducted every follow-up visit by Investigator, but particularly at baseline, Month 3rd, and end of study (Month 6th) by the Nutritionist. |
Study Type | Interventional |
Study Phase | Phase 3 |
Study Design | Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment |
Condition | Polycystic Ovary Syndrome (PCOS) |
Intervention | Drug: DLBS3233 1 DLBS3233 capsule 100 mg once daily for 6 months Other Names: InlacinDrug: Metformin XR 1 Metformin XR caplet 750 mg twice daily for 6 months Other Names: Glumin XRDrug: Placebo caplet of Metformin XR 1 placebo caplet of Metformin XR twice daily for 6 months Other Names: Placebo caplet of Glumin XRDrug: Placebo capsule of DLBS3233 1 placebo capsule of DLBS3233 once daily for 6 months Other Names: Placebo capsule of Inlacin |
Study Arm (s) |
|
Recruitment Information[ + expand ][ + ]
Recruitment Status | Recruiting |
---|---|
Estimated Enrollment | 124 |
Estimated Completion Date | February 2015 |
Estimated Primary Completion Date | December 2014 |
Eligibility Criteria | Inclusion Criteria: - Female subjects in reproductive age (i.e. 18-40 years) - Subject with a diagnosis of polycystic ovary syndrome confirmed by two of the Rotterdam Criteria - Subject with insulin resistance defined by: HOMA-IR of > 2.00 Exclusion Criteria: - Pregnant and lactating women - Subjects known to have Cushing's syndrome, late onset of congenital adrenal hyperplasia, androgen-secreting tumors, uncontrolled thyroid disease, hyperprolactinemia - Known to have current medical condition, which, is judged by the Investigator could jeopardize subject's health or interfere with the study evaluation, such as diabetes mellitus, uncontrolled hypertension, other cardiovascular diseases, acute or chronic infections, and any known malignancies - Impaired renal function (serum creatinine level > 1.5 ULN) - Impaired liver function (serum ALT level ≥ 2.5 ULN) - Medically-assisted weight loss with medications or surgical procedures - Currently having laparoscopic ovarian diathermy (LOD) - Currently under treatment with in vitro fertilization (IVF) techniques - Have been regularly taking any medications which affect insulin sensitivity as well as reproductive function (i.e. ovulation, menstrual cycle), within ≤ 3 months prior to screening - Participating in other clinical trial within 30 days prior to screening |
Gender | Female |
Ages | 18 Years |
Accepts Healthy Volunteers | No |
Contacts | Contact: Andon Hestiantoro, dr., SpOG(K) +62815 1052 6366 hestiantoro@gmail.com |
Location Countries | Indonesia |
Administrative Information[ + expand ][ + ]
NCT Number | NCT01733459 |
---|---|
Other Study ID Numbers | DLBS3233-0811 |
Has Data Monitoring Committee | No |
Information Provided By | Dexa Medica Group |
Study Sponsor | Dexa Medica Group |
Collaborators | Not Provided |
Investigators | Principal Investigator: Andon Hestiantoro, dr., SpOG(K) Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Indonesia, dr. Cipto Mangunkusumo Hospital, Jakarta, IndonesiaPrincipal Investigator: Wiryawan Permadi, Dr. dr., SpOG(K) Department of Obstetrics and Gynecology, Faculty of Medicine, University of Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia |
Verification Date | March 2014 |
Locations[ + expand ][ + ]
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Padjadjaran, Hasan Sadikin Hospital | Bandung, West Java, Indonesia, 40161 Contact: Wiryawan Permadi, Dr. dr., SpOG(K) | +62811 2090 06 | wiryawan_permadi@yahoo.comPrincipal Investigator: Wiryawan Permadi, Dr. dr., SpOG(K) Recruiting |
---|---|
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Indonesia, dr. Cipto Mangunkusumo Hospital | Jakarta, Indonesia, 10430 Contact: Andon Hestiantoro, dr., SpOG(K) | +62815 1052 6366 | hestiantoro@gmail.comPrincipal Investigator: Andon Hestiantoro, dr., SpOG(K) Recruiting |